乌鸦传媒視頻

We need more information on second-line treatment, says Barbara Eichhorst, MD

Hun Ju Lee, MD, breaks down the data on ibrutinib plus zilovertamab

Kerry Rogers, MD, discusses the next steps with obinutuzumab, ibrutinib, and venetoclax